All In Biotech

Investigational drug · Phase 2

RMC-9805

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for PDAC, Colorectal Cancer, CRC.

Phase 2

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

7

Any phase or sponsor naming "RMC-9805"

First trial start

2024

Jan 18, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "RMC-9805", any sponsor or status.

Conditions studied

As listed on its trial records.

  • PDAC
  • Colorectal Cancer
  • CRC
  • Pancreatic Ductal Adenocarcinoma
  • Gastrointestinal Cancer
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Non-Small Cell Lung Cancer, NSCLC
  • KRAS, NRAS, HRAS-mutated NSCLC
  • KRAS G12C-mutated Solid Tumors, Lung Cancer
  • Lung Cancer Stage IV, Advanced Solid Tumor, Cancer

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Pancreatic cancer · Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "RMC-9805" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 10 on PubMed

Also in development for PDAC

  • Telisotuzumab AdizutecanABBV-400Phase 316 trials

    AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer

  • IfebemtinibIN10018, BI853520Phase 311 trials

    InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer

  • GEMPhase 35 trials

    Shenzhen Majory Biotechnology Co., Ltd. · Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Cancer, Recurrent or Metastatic Cervical Cancer

  • AtebimetinibIMM-1-104, Group APhase 34 trials

    Immuneering Corporation · Pancreatic Adenocarcinoma, Advanced Solid Tumor, Malignant Melanoma (Cutaneous)

  • zoldonrasibPhase 34 trials

    Revolution Medicines, Inc. · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC

  • GFH276Phase 25 trials

    Genfleet Therapeutics (Shanghai) Inc. · RAS Mutation, Pancreatic Cancer, Non-small Cell Lung Cancer (NSCLC)

  • RNK08954Phase 23 trials

    InxMed (Shanghai) Co., Ltd. · Solid Tumor Cancer, PDAC, KRAS G12D Mutations

  • TNG462Phase 23 trials

    Tango Therapeutics, Inc. · MTAP-deleted Solid Tumors, Locally Advanced Solid Tumor, PDAC

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.